Durata Therapeutics to Host Conference Call and Webcast on December 11, 2012
at 9:00AM ET to Present Preliminary Top-line Results from its DISCOVER 1
CHICAGO -- December 10, 2012
Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that it will host a
conference call and webcast at 9:00am Eastern Time on Tuesday, December 11,
2012 to present preliminary top-line results from its DISCOVER 1 (“Dalbavancin
for Infections of the Skin COmpared to Vancomycin at an Early Response”) Phase
3 study of dalbavancin, which is under investigation for the treatment of
acute bacterial skin and skin structure infections (ABSSSI) caused by
susceptible gram-positive bacteria.
To access the call, please dial 866-632-4021 for participants in the U.S. or
Canada and 404-991-3968 for international callers, reference passcode:
79502265. A replay of the call may be accessed through December 25, 2012 by
dialing 800-585-8367 for callers in the U.S. and Canada and (404) 537-3406 for
international callers, reference passcode: 79502265. The conference call will
also be webcast live on Durata’s website, www.duratatherapeutics.com.
Dalbavancin is an intravenous antibiotic product candidate under investigation
for once-weekly dosing, which we believe may facilitate the treatment of
patients with ABSSSI in both the in-patient and out-patient settings,
potentially reducing the length of a patient’s hospital stay or avoiding
hospital admission altogether, with an impact on the overall cost of care for
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 trials with its
lead product candidate, dalbavancin, for the treatment of patients with acute
bacterial skin and skin structure infections, or ABSSSI.
Statements contained in this press release contain forward-looking statements
that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this press release, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and objectives of
management, are forward-looking statements. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.
Forward-looking statements in this press release include statements about the
potential benefits of dalbavancin. Actual results may differ materially from
those indicated by these forward-looking statements as a result of various
important factors, including those discussed in the “Risk Factors” section of
our most recent quarterly report on Form 10-Q, which is on file with the SEC
and is also available on our website. In addition, any forward-looking
statements represent our views only as of today and should not be relied upon
as representing our views as of any subsequent date. While we may elect to
update these forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so, even if our views change.
Therefore, you should not rely on these forward-looking statements as
representing our views as of any date subsequent to today.
Investor Relations and Public Affairs Contact:
Vice President, Investor Relations and Public Affairs
Press spacebar to pause and continue. Press esc to stop.